Inhibition of expression of human immunodeficiency virus-1 in vitro by antibody-targeted liposomes containing antisense RNA to the env region.
Previous studies revealed that antisense oligodeoxynucleotides to specific regions of the human immunodeficiency virus-1 (HIV-1) are potent inhibitors of replication of HIV-1 in vitro (Zamecnik, P. C., Goodchild, J., Taguchi, Y., and Sarin, P. S. (1986) Proc. Natl. Acad. Sci. U. S. A. 83, 4143-4146). We now report that antisense RNA, synthesized in vitro using T7 and SP6 RNA polymerase, displayed an anti-HIV-1 effect in the HTLV-IIIB/H9 system in vitro. Treatment of HIV-1-infected H9 cells with viral env region antisense RNA encapsulated in liposomes targeted by antibodies specific for the T cell receptor molecule CD3 almost completely inhibited HIV-1 production. The viral env segment covered a part of exon II of HIV-1 tat gene. No anti-HIV activity could be detected with similarly targeted liposome-encapsulated sense env RNA or with pol RNA synthesized in either the sense or antisense orientations, or with env region antisense RNA free in solution, or encapsulated in liposomes in the absence of the targeting antibody. A semiquantitative evaluation revealed that 4000-7000 RNA molecules became cell-bound in targeted liposomes; the half-life of the intracellularly present hybridizable antisense env RNA was approximately 12 h. Western blots showed that antisense env RNA suppressed tat gene expression by approximately 90% and gp160 production by 100%. These data were confirmed by immunoprecipitation studies. Northern blots (using an env probe) demonstrated the existence of all major HIV RNA species (9.3-, 4.3-, and 2.0-kb mRNA) in HIV-infected cells treated with antisense env RNA although at a reduced level. We conclude that the antisense env RNA inhibited viral protein production at the translational level.
Renneisen
K
K
Abteilung Angewandte Molekularbiologie, Universität, Mainz, German Democratic Republic.
Leserman
L
L
Matthes
E
E
Schröder
H C
HC
Müller
W E
WE
D000998:Antiviral Agents; D002460:Cell Line; D005814:Genes, Viral; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics* / Q000502:physiology; D006801:Humans; D008081:Liposomes; D010957:Plasmids; D012313:RNA / Q000494:pharmacology*; D016372:RNA, Antisense; D012333:RNA, Messenger / Q000037:antagonists & inhibitors*; D013205:Staphylococcal Protein A; D014158:Transcription, Genetic / Q000187:drug effects; D014759:Viral Envelope Proteins / Q000235:genetics*; D014779:Virus Replication / Q000187:drug effects*
D000998:Antiviral Agents; D008081:Liposomes; D016372:RNA, Antisense; D012333:RNA, Messenger; D013205:Staphylococcal Protein A; D014759:Viral Envelope Proteins; D012313:RNA